Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Financing Activities (2016 - 2025)

Ocular Therapeutix has reported Cash from Financing Activities over the past 13 years, most recently at $449.4 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $449.4 million for Q4 2025, up 9857.37% from a year ago — trailing twelve months through Dec 2025 was $561.7 million (up 69.14% YoY), and the annual figure for FY2025 was $561.7 million, up 69.14%.
  • Cash from Financing Activities for Q4 2025 was $449.4 million at Ocular Therapeutix, up from $10.4 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for OCUL hit a ceiling of $449.4 million in Q4 2025 and a floor of -$1.2 million in Q1 2021.
  • Median Cash from Financing Activities over the past 5 years was $3.4 million (2021), compared with a mean of $53.4 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 109.07% in 2021 and later surged 411724.36% in 2024.
  • Ocular Therapeutix's Cash from Financing Activities stood at $667000.0 in 2021, then crashed by 31.33% to $458000.0 in 2022, then surged by 23517.9% to $108.2 million in 2023, then plummeted by 95.83% to $4.5 million in 2024, then skyrocketed by 9857.37% to $449.4 million in 2025.
  • The last three reported values for Cash from Financing Activities were $449.4 million (Q4 2025), $10.4 million (Q3 2025), and $97.8 million (Q2 2025) per Business Quant data.